Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.

  • Zentalis Pharmaceuticals' Consolidated Net Income rose 3353.5% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 1673.86%. This contributed to the annual value of -$165.9 million for FY2024, which is 3996.66% up from last year.
  • Zentalis Pharmaceuticals' Consolidated Net Income amounted to -$26.7 million in Q3 2025, which was up 3353.5% from -$26.9 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Consolidated Net Income peaked at $10.0 million during Q1 2024, and registered a low of -$98.9 million during Q2 2023.
  • Moreover, its 4-year median value for Consolidated Net Income was -$52.1 million (2022), whereas its average is -$51.0 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first surged by 11647.2% in 2024, then tumbled by 58086.65% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Consolidated Net Income stood at -$48.2 million in 2022, then dropped by 26.53% to -$60.9 million in 2023, then increased by 22.1% to -$47.5 million in 2024, then surged by 43.78% to -$26.7 million in 2025.
  • Its Consolidated Net Income stands at -$26.7 million for Q3 2025, versus -$26.9 million for Q2 2025 and -$48.3 million for Q1 2025.